GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

OBJECTIVES:

Primary

• Determine the safety and tolerability of daily neoadjuvant sargramostim (GM-CSF) in patients with localized prostate cancer undergoing radical prostatectomy.
• Determine whether tissue-specific antiprostate cancer immunity is induced by the administration of neoadjuvant GM-CSF in patients with localized prostate cancer prior to radical prostatectomy.

Secondary

• Estimate the baseline antitumor immune response in patients treated with 2 different dose schedules of GM-CSF.
• Determine the magnitude of the difference in immune response between 2 dose schedules of GM-CSF.
• Determine the clinical effects, including prostate-specific antigen (PSA) decline, surgical outcome, surgical complications, and histologic appearance of surgical specimen, of this regimen in these patients.

OUTLINE: This is a pilot study. Patients are stratified according to sargramostim (GM-CSF) dose.

Patients receive 1 of 2 dose levels of GM-CSF subcutaneously on days 1-14 or 1-21. Treatment continues in the absence of unacceptable toxicity. Within 3 days after the last dose of GM-CSF, patients undergo radical prostatectomy.

Blood is collected at baseline, day 28 of each course, and at the 4-week follow-up visit and is examined for activated T-cells. Tissue is collected during surgery and assessed for biomarkers and cytokines.

After completion of study treatment, patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed adenocarcinoma of the prostate

• No neuroendocrine or small cell features
• No evidence of metastatic disease
• Planning radical prostatectomy at least 2 months from now
• Testosterone level normal

PATIENT CHARACTERISTICS:

• ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 8 g/dL
• AST and ALT ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• Creatinine ≤ 1.5 times ULN
• PT and PTT normal
• Fertile patients must use effective barrier contraception
• No history of allergic reaction to compounds of similar chemical or biologic composition to sargramostim (GM-CSF)
• No ongoing or active bacterial, viral, or fungal infection
• DLCO > 50% if patient has a history of clinically significant obstructive airway disease
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No other active malignancy, defined as cancer for which therapy has been completed and patient is now considered < 30% risk of relapse, except nonmelanoma skin cancer
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• No underlying medical condition that, in the opinion of the principal investigator, may make the administration of GM-CSF hazardous or obscure the interpretation of adverse events

PRIOR CONCURRENT THERAPY:

• More than 4 weeks since prior major surgery
• No prior radiotherapy, immunotherapy, chemotherapy, or other investigational therapy for this cancer
• No prior hormonal therapy including any of the following:

• Luteinizing-hormone releasing hormone (LHRH) agonists
• LHRH antagonists
• Antiandrogens, including any of the following:

• Bilcalutamide
• Flutamide
• Nilutamide
• 5-alpha-reductase inhibitors
• PC-SPES or other PC-x product
• Estrogen-containing nutriceuticals
• No concurrent chemotherapy or radiotherapy
• No concurrent systemic steroid therapy

• Concurrent inhaled or topical steroids allowed
• No other concurrent immunotherapy
• No other concurrent investigational agent
• No other concurrent anticancer agents or therapies